Press releases
- Press releases
- Browse
Press releases
TNO BIBRA is happy to announce the appointment of Associate Professor John Lambert to run their Phase I Clinical Studies Department More
Tamarkin Pharmaceutical Innovation Ltd. (TPI) initiates a Phase II clinical trial, aimed to evaluate the effectiveness of TU-2100 for seborrheic dermatitis. The trial is set to begin in January 2000 More
Tamarkin Pharmaceutical Innovation Ltd. (TPI) announced successful completion of a Phase II study in acne patients. According to the study results, TU-2100 may become the next treatment of choice for acne sufferers. More
Related Reports
Market Research Reports provided by reports.iptechex.com
Jun 2006 - 434 pages - $2,495
Feb 2006 - 332 pages - $3,900
Jul 2011 - 96 pages - $3,835
Dec 2007 - 49 pages - $495
Oct 2011 - 89 pages - $3,500
Jan 2008 - 330 pages - $4,200
Nov 2009 - 142 pages - $2,350
Nov 2010 - 189 pages - $2,350
Jan 2010 - 250 pages - $3,900
Jan 2010 - $75
Your selection
Browse By
- Industry sector
- Academic/Research
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Non-profit org./Government
- Pharmaceutical
- Research tools
- Service
- Therapeutic target
- Acne
- Actinic keratosis
- Alopecia
- Bacterial infection
- Burns
- Chronic idiopathic urticaria
- Cosmetic procedures
- Dermal ulcers
- Dermatitis, allergic
- Dermatitis, atopic
- Dermatological (other)
- Dermatosis
- Eczema
- Fungal infection
- Hirsutism
- Human B19 parvovirus
- Hyperkeratosis
- Ichthyosis
- Impetigo
- Insect bite
- Keloids
- Lupus
- Male pattern baldness
- Paget's disease
- Photodamage
- Pruritis
- Psoriasis
- Scleroderma
- Shingles
- Skin infection (other)
- Ulcer, diabetic
- Urticaria
- Wound healing
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us